What's Happening?
Humana Inc. has significantly improved its Medicare Advantage star ratings, with 95% of its members now enrolled in plans rated four stars or higher for 2027. This marks a substantial recovery from a year ago, when only 20% of its Medicare Advantage members were
in such highly-rated plans. This previous decline had led to an estimated $3.5 billion net revenue headwind for the company. The Centers for Medicare & Medicaid Services (CMS) released these 2027 star ratings in October 2026. In its third-quarter results, Humana reported $41.2 billion in revenue, an increase from $32.6 billion in the prior year, and its insurance segment benefit ratio was 93.7%, outperforming its guidance. The company's health services division, CenterWell, also saw growth, adding nearly 147,000 primary care patients year-to-date and generating $7.2 billion in revenue. Humana also announced a new joint venture with HPS, now part of BlackRock, replacing earlier partnerships.
Why It's Important?
This turnaround in star ratings is crucial for Humana, as these ratings directly influence eligibility for government quality bonus payments. Analysts at Evercore ISI estimate that these improved ratings could generate approximately $4.8 billion in government bonus payments for Humana in 2028. The ultimate financial impact will depend on how much of this additional funding Humana reinvests into member benefits and provider arrangements. The company's CEO, Jim Rechtin, indicated that early enrollment activity for the annual enrollment period is exceeding expectations, suggesting a potential increase in membership for 2027. This positive outlook follows a period where Humana exited plans covering approximately 600,000 members, strategically targeting lower-rated contracts to reduce exposure on underperforming books and facilitate its star ratings recovery. The company's CFO, Celeste Mellet, also attributed some of the outperformance to strong relationships with broker partners and consolidation among smaller plans benefiting larger carriers.
What's Next?
Humana anticipates an increase in its Medicare Advantage membership for 2027, based on strong early enrollment activity during the annual enrollment period, which concludes on December 7. The company's restructured joint venture with HPS is expected to lower its cost of capital and eliminate a put option that would have required funding in 2027, thereby freeing up balance sheet capacity ahead of the anticipated bonus payments in 2028. The company will likely focus on maintaining its improved star ratings and leveraging the potential $4.8 billion in government bonus payments to further enhance member benefits and provider arrangements. The impact of the previous commission cuts on selected plans, a tactic used to manage unprofitable growth, will also be a point of observation as the company moves forward with its renewed growth strategy.
Beyond the Headlines
The significant fluctuation in Humana's star ratings and its subsequent recovery highlight the profound impact of regulatory frameworks, such as CMS star ratings, on the financial health and operational strategies of major healthcare insurers. The decision to exit certain plans and adjust broker commissions underscores the complex interplay between profitability, regulatory compliance, and market competition in the Medicare Advantage sector. This situation also sheds light on the evolving landscape of healthcare partnerships, with Humana's new joint venture with HPS (now part of BlackRock) indicating a strategic shift towards optimizing capital structure and operational efficiency. The emphasis on reinvesting potential bonus payments into member benefits and provider arrangements suggests a long-term strategy to enhance value and maintain competitive advantage in a highly regulated and competitive market.
